Peres Tobias, Aeppli Stefanie, Fischer Stefanie, Rothermundt Christian
Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), St. Gallen, Switzerland.
Department of Medical Oncology and Cancer Centre, Cantonal Hospital Lucerne (LUKS), Lucerne, Switzerland.
Front Oncol. 2025 Apr 11;15:1555897. doi: 10.3389/fonc.2025.1555897. eCollection 2025.
Prostate carcinoma (PC) is the most common cancer in men worldwide. However, brain metastases (BM) from prostate cancer are extremely rare events, usually in the later course of the disease. There is no established standard of care treatment for this situation. The efficacy of androgen synthesis inhibitor abiraterone in BM from PC is unknown.
We herein report the case of an 83-year-old patient with metastatic hormone-sensitive PC who had multiple BM at primary diagnosis, clinically manifesting with dizziness, ataxia, and unsteady gait. Combination of abiraterone and androgen deprivation therapy showed exceptional sustained cerebral tumor response. After 12 months of treatment, the patient is asymptomatic with an excellent performance status.
Symptomatic BM from PC is a rarity but can show sustained response to abiraterone and androgen deprivation therapy. After comprehensive literature search, there is no comparable case published to date.
前列腺癌(PC)是全球男性中最常见的癌症。然而,前列腺癌脑转移(BM)极为罕见,通常发生在疾病晚期。目前尚无针对这种情况的既定标准治疗方案。雄激素合成抑制剂阿比特龙在前列腺癌脑转移中的疗效尚不清楚。
我们在此报告一例83岁转移性激素敏感性前列腺癌患者,初诊时即有多处脑转移,临床表现为头晕、共济失调和步态不稳。阿比特龙与雄激素剥夺疗法联合使用显示出异常持久的脑肿瘤反应。治疗12个月后,患者无症状,身体状况良好。
前列腺癌引起的有症状脑转移很罕见,但对阿比特龙和雄激素剥夺疗法可表现出持久反应。经全面文献检索,迄今为止尚无类似病例发表。